New Test to Predict Primary Melanoma Progression
21 January 2020
Australian researchers have played a critical role in the discovery of a potential new test to predict which early stage melanoma patients are at high risk of their disease recurring and progressing.
A joint study led by researchers from Melanoma Institute Australia, The University of Sydney, Harvard Medical School, Sydney Local Health District and Adaptive Biotechnology analysed immune cells (known as T-cells) in primary melanoma samples taken from 209 patients, 164 of whom came from MIA.
The study, published today in Nature Cancer, found that patients with a T-cell fraction (TCFr) of less than 20% in their primary melanoma were two-and-a-half times more likely to have disease progression than those with more than 20% TCFr.
The study was jointly led by Dr James Wilmott and Co-Medical Director Professor Richard Scolyer from Melanoma Institute Australia and researchers from Harvard Medical School.
‘These findings suggest analysing TCFr in primary melanomas is a valuable tool for predicting which patients are at risk of developing metastatic melanoma, ’ Dr Wilmott said.
‘This could enable us to personalise treatment for each patient based on their individual risk of recurrence and progression, and potentially target them earlier with immunotherapy,’ Professor Scolyer added.
Australia has one of the highest melanoma rates in the world, with one person diagnosed every 30 minutes and one person dying every five hours from disease.
While 90% of early stage melanomas are cured with surgery alone, a subset of patients will recur metastatically within five years.
Recent advances in targeted and immunotherapies have significantly improved outcomes for Stage IV melanoma patients. However, the management of primary melanoma has remained relatively unchanged, with prognosis based principally on histopathological factors such as tumour thickness and ulceration.
‘This test offers the ability to identify primary melanoma patients at high risk of developing metastatic disease at their initial diagnosis,’ Dr Wilmott said. ‘These patients may benefit from close monitoring or the addition of adjuvant treatments to prevent their disease progressing.’
Sun Protection: Facts and Controversies
MIA's dermatologist shares her knowledge with GPs on debunking myths and controversies on sunscreen.
Shannan Ponton joins our March for a cure
Shannan Ponton thought he was invincible – he wasn’t. But his melanoma battle ended up saving more than his own life.
Surprising finding in rare form of melanoma get patients closer to personalised medicine
Researchers have demonstrated that immunotherapy is highly effective in treating a rare form of melanoma – a result that is surprising due to the nature of the tumour.
Using new technology to prevent melanoma
Innovation is helping to prevent melanoma developing in the first place.
Research review of 2017
Research from MIA is changing the way melanoma is managed worldwide and improving patient survival. Here are a few of our key highlights from this year.
Translational research funding boost
A prestigious Fellowship has been awarded to fund research that will change the way melanoma treatment is assessed in the future.
New research to guide clinicians to more accurately stage and manage melanoma patients
New research from MIA has been published that forms the basis of the updated international guidelines for staging melanoma.
Founding father recognised for outstanding cancer care
Professor William McCarthy AM has been awarded the Tom Reeve Award for Outstanding Contributions to Cancer Care.
Melanoma researchers shine at the State's premier cancer awards ceremony
Leading researchers from MIA have been acknowledged with three prestigious awards for excellence in melanoma research.
Enhancing melanoma treatment response through gut bacteria
New research shows that patients who are more likely to respond to immunotherapy treatment have a greater diversity in their gut bacteria.
Melanoma March is just around the corner!
2018 will be bigger than ever, and a little bit different.
Comparing melanoma risk in similar populations across different latitudes
MIA's epidemiologist explains her new research on how country of residence should be considered when identifying melanoma risk.
Congratulations to our Conjoint Medical Directors
Congratulations to our Conjoint Medical Directors, Professor Georgina Long and Professor Richard Scolyer, who have today been announced as Fellows of the Australian Academy of Health and Medical Sciences.
What causes melanoma in 90% of young Australians?
New research shows potentially deadly UV damage can appear decades earlier than you think.
Early lymph node check is saving lives in melanoma patients
Early lymph node check is saving lives in melanoma patients
Congratulations to Associate Professor Anne Cust
We are pleased to announce that A/Prof Anne Cust is the new President of the Australasian Epidemiological Association.
Smoking linked to increased risk of melanoma spreading
New research has shown that melanoma patients who smoke have an increased risk of their disease progressing compared to patients who do not smoke.
Research boost to improve outcomes for melanoma patients
More than $3.5 million in competitive funding grants have been awarded to MIA's researchers.
Highlights in melanoma research from ESMO
The ESMO conference provided a platform for announcing a number of key melanoma research findings - including practice-changing research from MIA.
Australian researchers stopping melanoma in its tracks
Australian researchers have successfully trialled a combination of new treatments to prevent melanoma from spreading to distant organs.